NasdaqCM:CLDXBiotechs
Celldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For Barzolvolimab
Celldex Therapeutics (CLDX) experienced a share price increase of 19% over the last quarter, following significant developments in its clinical programs. Recently, the company announced promising results from a Phase 2 study of barzolvolimab, which showed effective mast cell depletion in eosinophilic esophagitis, albeit without clinical symptom improvement. Additionally, barzolvolimab demonstrated positive outcomes in treating chronic spontaneous urticaria. While Celldex's earnings faced...